Form 4: Skye Bioscience Director Andrew J. Schwab Acquires 450,000 Shares

Director Andrew J. Schwab reports the acquisition of 450,000 shares of Skye Bioscience, Inc. common stock through indirect holdings.

Summary

• On March 13, 2024, Andrew J. Schwab, a director of Skye Bioscience, Inc., acquired 450,000 shares of common stock.
• The shares were acquired at a price of $10 per share.
• Following the transaction, Schwab indirectly holds 8,393,520 shares through 5AM Ventures VII, L.P., 1,718,189 shares through 5AM Ventures II, L.P., and 67,796 shares through 5AM Co-Investors II, L.P..
• Schwab disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the purchase of shares by a director can be seen as a positive sign, the indirect nature of the ownership and the disclaimer of beneficial ownership (beyond pecuniary interest) temper the enthusiasm.

Positives

• The acquisition of shares by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Risks

• The filing indicates indirect ownership and disclaims beneficial ownership except for pecuniary interest, which could suggest a limited direct stake in the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, and principal stockholders) of a publicly traded company buy or sell the company's securities. These filings provide transparency into insider transactions and can be used by investors to gauge management's sentiment about the company's prospects.

Comparison to Industry Standards

• Comparing this transaction to similar insider purchases in comparable biotech companies would require analyzing the size of the purchase relative to Schwab's existing holdings and the company's market capitalization.
• It would also be useful to compare the timing of this purchase with other insider transactions at Skye Bioscience and its peers.

Stakeholder Impact

• The acquisition of shares by a director could potentially increase investor confidence in Skye Bioscience.

Key Dates